OWC Pharmaceutical Research Corp. - Quarter Report: 2009 June (Form 10-Q)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x          QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended June 30, 2009

o           TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 333-148664

DYNAMIC APPLICATIONS CORP.

(Exact name of small business issuer as specified in its charter)

Delaware	98-0573566
(State of incorporation)	(IRS Employer ID Number)

C/o Beit Gibor Sport

7 Menachem Begin Street

Ramat Gan ISRAEL 52521

(Address of principal executive offices)

972 - (3) 611-6262

(Issuer's telephone number)

46 Techelet Street Modiin Israel 71700

(Former name, former address and former fiscal year, if changed since last report)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer                           ¨		Accelerated filer                                                       ¨
Non-accelerated filer                            ¨		Smaller reporting company                                    x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of  July 31  2009 there were 86,145,000 shares of common stock outstanding .

---

TABLE OF CONTENTS

		Page
PART I
Item 1. Financial Statements			F-1
Item 2. Management’s Discussion and Analysis or Plan of Operation			3
Item 3 Quantitative and Qualitative Disclosures About Market Risk			6
Item 4 Controls and Procedures			6
Item 4(T) Controls and Procedures			6
PART II
Item 1. Legal Proceedings			6
Item IA. Risk Factors			6
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			7
Item 3. Defaults Upon Senior Securities			7
Item 4. Submission of Matters to a Vote of Security Holders			7
Item 5. Other Information			7
Item 6. Exhibits			7

PART I

FINANCIAL INFORMATION

 

 

 

 

 

 

 

 

 

 

 

The Company has currently ceased to pursue the development of the patent.